Remarkable progress has been made in the treatment of hairy cell leukemia (HCL) in the past 30 years, but often control rather than cure of the disease is obtained. Purine analogues are considered the best treatment, but the optimal strategy is still debated. Allogeneic stem cell transplantation (allo-SCT) is yet an anecdotal therapeutic option for patients who have had multiple relapses of HCL. We describe the case of a young patient with HCL who was treated with several therapeutic approaches without any significant response. Conceivably, this report represents further important evidence of the potential role of allo-SCT in heavily pretreated patients with late-stage HCL.

Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients / Zinzani PL; Bonifazi F; Pellegrini C; Casadei B; Argnani L; Motta MR; Dan E; Stanzani M; Arpinati M; Bandini G.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - STAMPA. - 12:(2012), pp. 287-289. [10.1016/j.clml.2012.05.001]

Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients.

ZINZANI, PIER LUIGI;BONIFAZI, FRANCESCA;PELLEGRINI, CINZIA;CASADEI, BEATRICE;ARGNANI, LISA;MOTTA, MARIA ROSA;DAN, ELISA;STANZANI, MARTA;ARPINATI, MARIO;BANDINI, GIUSEPPE
2012

Abstract

Remarkable progress has been made in the treatment of hairy cell leukemia (HCL) in the past 30 years, but often control rather than cure of the disease is obtained. Purine analogues are considered the best treatment, but the optimal strategy is still debated. Allogeneic stem cell transplantation (allo-SCT) is yet an anecdotal therapeutic option for patients who have had multiple relapses of HCL. We describe the case of a young patient with HCL who was treated with several therapeutic approaches without any significant response. Conceivably, this report represents further important evidence of the potential role of allo-SCT in heavily pretreated patients with late-stage HCL.
2012
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients / Zinzani PL; Bonifazi F; Pellegrini C; Casadei B; Argnani L; Motta MR; Dan E; Stanzani M; Arpinati M; Bandini G.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - STAMPA. - 12:(2012), pp. 287-289. [10.1016/j.clml.2012.05.001]
Zinzani PL; Bonifazi F; Pellegrini C; Casadei B; Argnani L; Motta MR; Dan E; Stanzani M; Arpinati M; Bandini G.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/120201
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 8
social impact